Trial Profile
Selective COX-II inhibitor as a palliative therapy in patients with R1 or R2 resection for disseminated stomach cancer - a multi-centre prospective randomized controlled trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Rofecoxib (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 31 Oct 2006 New trial record.